Solid lipid nanoparticles are typically spherical in shape with average size of 1-1000nm in diameter. These are the alternatives to traditional colloidal carrier systems such as emulsions, liposomes, microspheres etc. Felbamate is a PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA receptors. It is used as an anticonvulsant, primarily for the treatment of seizures in severe refractory epilepsy. It is slightly soluble in water with t1/2 of 4-6 hours. Solid lipid nanoparticles of felbamate are prepared by using lipids (glyceryl monostearate and glyceryl monooleate) with tween 80 as stabilizer. The prepared nanoparticle formulations were evaluated for their entrapment efficiency, assay, in-vitro drug release, particle size analysis, and stability. A formulation containing glyceryl monooleate, stabilized with tween 80 as surfactant showed prolonged drug release, smaller particle size, and narrow particle size distribution, as compared to other formulations.
Cite this article:
Ramanuj Prasad Samal, Pratap Kumar Sahu. Formulation and Evaluation of Solid Lipid Nanoparticle of Felbamate for improved Drug Delivery. Research J. Pharm. and Tech. 2021; 14(1):285-288. doi: 10.5958/0974-360X.2021.00051.2
Ramanuj Prasad Samal, Pratap Kumar Sahu. Formulation and Evaluation of Solid Lipid Nanoparticle of Felbamate for improved Drug Delivery. Research J. Pharm. and Tech. 2021; 14(1):285-288. doi: 10.5958/0974-360X.2021.00051.2 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-1-51
1. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. International Journal of Pharmaceutics. 2011; 420 (1): 1–10.
2. Das S, Ng WK, Kanaujia P, Kim S, Tan RB. Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug: Effects of process variables. Colloids and Surfaces B: Biointerfaces. 2011; 88 (1): 483–489.
3. Harde H, Das M, Jain S. Solid lipid nanoparticles: An oral bioavailability enhancer vehicle. Expert Opinion on Drug Delivery. 2011; 8 (11): 1407–1424.
4. Sarmento B, Martins S, Ferreira D, Souto EB. Oral insulin delivery by means of solid lipid nanoparticles. International Journal of Nanomedicine. 2007; 2 (4): 743–749.
5. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. European Journal of Pharmaceutics and Biopharmaceutics. 2000; 50 (1): 161–177.
6. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. Advanced Drug Delivery Reviews. 2001; 47 (2-3): 165–196.